COCP SCHEDULE 13D/A: SEC filing
An amendment to a Schedule 13D was
Filed with the SEC on · accession 0000944809-26-000003
COCP filed a SCHEDULE 13D/A (schedule 13d/a) with the SEC on Nov 6, 2026. An amendment to a Schedule 13D was filed for Cocrystal Pharma, Inc. (COCP), indicating a change in a previously reported beneficial ownership position.
Summary of the filing
An amendment to a Schedule 13D was filed for Cocrystal Pharma, Inc. (COCP), indicating a change in a previously reported beneficial ownership position. The filing text provided is only an EDGAR directory listing and does not disclose the specific ownership details or the nature of the amendment.
Key details
✦ Ask GOAX AI about this filing — what it means for COCP, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for COCP?
Click hereFrequently asked questions
What did COCP file with the SEC on Nov 6, 2026?
COCP filed a SCHEDULE 13D/A (SEC filing). An amendment to a Schedule 13D was filed for Cocrystal Pharma, Inc. (COCP), indicating a change in a previously reported beneficial ownership position. The filing text provided is only an EDGAR directory listing and does not disclose the specific ownership details or the nature of the amendment.
How do I read a SCHEDULE 13D/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D/A (schedule 13d/a): A report the company filed with the SEC (the US market regulator).
Other COCP SEC filings
- 8-K · Fda approvalSep 9, 2026
- 8-K · Board changeAug 18, 2026
- 8-K · Board changeAug 17, 2026
- 10-Q · SEC filingAug 13, 2026
- 8-K · Material agreementAug 3, 2026
- 8-K · Board changeJul 17, 2026
- 8-K · Ceo changeJun 9, 2026
- 8-K · Ceo changeJun 3, 2026
- DEF 14A · Board changeMay 27, 2026
- 8-K · Fda approvalMay 26, 2026
Get alerts when COCP files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days